[Peculiarities and difficulties in the systematic drug therapy of chronic schizophrenics (schizophrenic "defect")].
Difficulties are discussed that have occurred in the medicamentous treatment of chronic patients with a so-called schizophrenic defect. The main problem was that in case of a greater drive-increasing effect component of the drug (in the concrete case "Defecton") a recrudescence of productive-schizophrenic symptoms may occur in connection with the increase in drive. The authors' own opinion (Lange) with respect to a treatening "defect", psychopathological radical of the chronic schizophrenic residual condition ("defect"), personality-dependent syndrome structure with secondary symptoms, iaterogenisation and institutiogenisation of the "defect" ("institution artefact") is discussed.
D000328:Adult; D014151:Anti-Anxiety Agents; D001569:Benzodiazepines; D002908:Chronic Disease; D003984:Dibenzazepines / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy*; D012565:Schizophrenic Psychology
D014151:Anti-Anxiety Agents; D003984:Dibenzazepines; D001569:Benzodiazepines; C006922:carpipramine
Besonderheiten und Schwierigkeiten beim gezielten medikamentösen Einsatz in der Behandlung von chronisch Schizophrenen (schizophrener "Defekt").